Ikena reports Q3 cash $196.9M, IK-930 shows stable disease in all 7 EHE patients

ImageneBio, Inc.

Q3 2023 cash, cash equivalents and marketable securities of $196.9M; runway into 2026.
IK-930 dose escalation: 26 patients treated; 7/7 EHE patients achieved stable disease, 3 with tumor shrinkage.
Treatment-related proteinuria in 3/26 patients, all grade 1-2, no dose reductions or interruptions.
IK-595 clinical trial expected to initiate by end of 2023; IK-930 data update planned for H2 2024.
Collaboration revenue $1.2M vs $6.4M YoY; R&D expenses $14.7M vs $18.9M YoY.

item 2.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

ImageneBio, Inc. reported financial results for the quarter ended September 30, 2023.

Period: the quarter ended September 30, 2023
Result: reported results

Exact text from the filing

On November 9, 2023, Ikena Oncology, Inc. (the “Company”) announced its financial results for the quarter ended September 30, 2023.

View on SEC.gov

18 earnings releases filed in the last 30 days. Browse all earnings releases →

ImageneBio, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-061519

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.